Spectrum Pharmaceuticals, Inc. Out-Licenses Rights For Greater China To CASI Pharmaceuticals For Three Of Its Drugs
HENDERSON, Nev. & ROCKVILLE, Md.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, and CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary focus on China, announce the signing of license agreements whereby CASI has been granted exclusive rights to two of Spectrum Pharmaceuticals’ commercial oncology drugs, Zevalin® (ibritumomab tiuxetan) Injection for intravenous use and Marqibo® (vinCRIStine sulfate LIPOSOME injection) for intravenous infusion, and a Phase 3 drug candidate, Captisol-Enabled™ Melphalan (CE melphalan), for development and commercialization in China, including Taiwan, Hong Kong and Macau.
Help employers find you! Check out all the jobs and post your resume.